Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors

NCT05252416 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.

NCT NCT05252416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05252416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors
Lead sponsor
Blueprint Medicines Corporation
Phase
Phase 1
Overall status
Terminated
Start date
April 7, 2022
Completion date
July 4, 2025
Enrollment
50 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, carcinosarcoma, ccne1 amplification, endometrial cancer, esophageal adenocarcinoma, gastric cancer, her2-negative breast cancer, hr+ breast cancer, ovarian cancer